J9313 Injection., lumoxiti, 0.01 milligrams
Also known as: lumoxiti, Lumoxiti
Injection of lumoxiti, 0.01 milligram. A recombinant immunotoxin targeting CD25 for cutaneous T-cell lymphomas.
In Plain Language
lymphoma injection; T-cell cancer treatment
Clinical Context
Used for cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Targets CD25-positive malignant T-cells.
RVU Information
CPT J9313 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9313?
CPT J9313 (Injection., lumoxiti, 0.01 milligrams) is a J Codes (Drugs) code. Injection of lumoxiti, 0.01 milligram. A recombinant immunotoxin targeting CD25 for cutaneous T-cell lymphomas.
How is J9313 administered?
CPT J9313 is administered by a healthcare provider, typically via injection or infusion. Used for cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Targets CD25-positive malignant T-cells. It is used by Oncology, Dermatology, Hematology.
When is CPT J9313 used?
Used for cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Targets CD25-positive malignant T-cells.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.